Sector News

Drugmaker Abbott says not pursuing an offer for St Jude Medical

August 31, 2015
Life sciences

(Reuters) – Drugmaker Abbott Laboratories, knocking down a report in the Financial Times, denied on Thursday that it was preparing a bid for medical device maker St Jude Medical Inc.

The FT, citing people familiar with the matter, reported that Abbott has been working with advisers for several weeks to line up financing for a $25 billion cash and stock bid for St. Paul, Minnesota-based St Jude. St Jude’s shares, which jumped 15 percent premarket trading following the report, were up 3.4 percent at $71.72 in early trading.

The company had a market value of about $19.5 billion as of Wednesday’s close.

“I can tell you that we are not pursuing an offer for St Jude,” Abbott spokesman Scott Stoffel told Reuters.

St Jude did not immediately respond to a request for comment.

A source familiar with Abbott’s thinking said he did not believe a deal was seriously contemplated, while Evercore ISI analyst Vijay Kumar said Abbott was more likely to do medium-sized deals than a big transaction.

Abbott Chief Executive Miles White said last month that he was interested in acquisitions, including in the device sector, but would be cautious because a flurry of deals in the healthcare industry had pushed up valuations.

Abbott had cash on hand of almost $4 billion as of June 30.

RBC Capital Markets analyst Glenn Novarro said last month that a deal in the region of $5 billion for a device maker was more likely than something larger.

Kumar and Wells Fargo Securities’ Larry Biegelsen said on Thursday they expected Abbott to strike a deal in either the medical device or generic drug industries.

Abbott shares, which had fallen about 2 percent this year up to Wednesday’s close, were up 1.8 percent at $44.75.

By Vidya L Nathan

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach